UNAUDITED INTERIM CONDENSED STATEMENTS OF CHANGES IN EQUITY |
Common Stocks [Member]
USD ($)
shares
|
Common Stocks [Member]
KRW (₩)
shares
|
Other reserves
USD ($)
|
Other reserves
KRW (₩)
|
Retained earnings
USD ($)
|
Retained earnings
KRW (₩)
|
USD ($) |
KRW (₩) |
CubeBio Co., Ltd. [Member]
KRW (₩)
|
Share capital [Member]
CubeBio Co., Ltd. [Member]
KRW (₩)
|
Share premium [member]
CubeBio Co., Ltd. [Member]
KRW (₩)
|
Share subscription receivable [Member]
CubeBio Co., Ltd. [Member]
KRW (₩)
|
Other reserves [member]
CubeBio Co., Ltd. [Member]
KRW (₩)
|
Accumulated other comprehensive income [member]
CubeBio Co., Ltd. [Member]
KRW (₩)
|
Retained earnings [member]
CubeBio Co., Ltd. [Member]
KRW (₩)
|
Total [Member]
CubeBio Co., Ltd. [Member]
KRW (₩)
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beginning balance, value at Dec. 31, 2023 | ₩ 23,808,105,000 | ₩ 32,610,201,000 | ₩ 1,340,781,000 | ₩ 201,386,000 | ₩ (61,351,244,000) | ₩ (3,390,771,000) | ||||||||||
| IfrsStatementLineItems [Line Items] | ||||||||||||||||
| Net income (loss) | ₩ (8,065,334,000) | |||||||||||||||
| Loss for the period | (8,065,334,000) | (8,065,334,000) | ||||||||||||||
| Remeasurement of defined benefit liabilities | (127,853,000) | (127,853,000) | ||||||||||||||
| Total comprehensive loss for the period | (127,853,000) | (8,065,334,000) | (8,193,187,000) | |||||||||||||
| Warrants exercised | 1,312,333,000 | 5,882,662,000 | 7,194,995,000 | |||||||||||||
| Bond with warrants issued | 176,911,000 | 176,911,000 | ||||||||||||||
| Stock option exercised | 1,026,800,000 | 2,324,675,000 | (2,324,675,000) | 1,026,800,000 | ||||||||||||
| Stock option expired | 100,092,000 | (100,092,000) | ||||||||||||||
| Disposal of treasury shares | 3,655,077,000 | 356,783,000 | 4,011,860,000 | |||||||||||||
| Ending balance, value at Dec. 31, 2024 | $ 50,000 | ₩ 50,000 | $ (29,753) | ₩ (29,753) | $ 20,247 | ₩ 20,247 | 26,147,238,000 | 44,749,618,000 | (727,203,000) | 73,533,000 | (69,416,578,000) | 826,608,000 | ||||
| Ending balance, Shares at Dec. 31, 2024 | shares | 50,000 | 50,000 | ||||||||||||||
| Beginning balance, value at Sep. 24, 2024 | $ | ||||||||||||||||
| Beginning balance, Shares at Sep. 24, 2024 | shares | ||||||||||||||||
| IfrsStatementLineItems [Line Items] | ||||||||||||||||
| Shares issued for related party receivable | $ | $ 50,000 | 50,000 | ||||||||||||||
| Shares issued for related party receivable, shares | shares | 50,000 | 50,000 | ||||||||||||||
| Net income (loss) | $ | (29,753) | (29,753) | ||||||||||||||
| Ending balance, value at Dec. 31, 2024 | $ 50,000 | ₩ 50,000 | (29,753) | (29,753) | 20,247 | 20,247 | 26,147,238,000 | 44,749,618,000 | (727,203,000) | 73,533,000 | (69,416,578,000) | 826,608,000 | ||||
| Ending balance, Shares at Dec. 31, 2024 | shares | 50,000 | 50,000 | ||||||||||||||
| IfrsStatementLineItems [Line Items] | ||||||||||||||||
| Net income (loss) | 456 | 456 | (3,400,181,000) | |||||||||||||
| Loss for the period | (3,400,181,000) | (3,400,181,000) | ||||||||||||||
| Remeasurement of defined benefit liabilities | 26,061,000 | 26,061,000 | ||||||||||||||
| Total comprehensive loss for the period | 26,061,000 | (3,400,181,000) | (3,374,120,000) | |||||||||||||
| Disposal of treasury shares | 100,000,000 | 163,089,000 | (100,000,000) | 36,911,000 | 100,000,000 | |||||||||||
| Issuance of bond with warrants | 61,326,000 | 61,326,000 | ||||||||||||||
| Ending balance, value at Jun. 30, 2025 | $ 50,000 | (29,297) | 20,703 | 26,147,238,000 | 44,974,033,000 | (100,000,000) | (690,292,000) | 99,594,000 | (72,816,759,000) | (2,386,186,000) | ||||||
| Ending balance, Shares at Jun. 30, 2025 | shares | 50,000 | 50,000 | ||||||||||||||
| Beginning balance, value at Dec. 31, 2024 | $ 50,000 | ₩ 50,000 | (29,753) | (29,753) | 20,247 | 20,247 | 26,147,238,000 | 44,749,618,000 | (727,203,000) | 73,533,000 | (69,416,578,000) | 826,608,000 | ||||
| Beginning balance, Shares at Dec. 31, 2024 | shares | 50,000 | 50,000 | ||||||||||||||
| IfrsStatementLineItems [Line Items] | ||||||||||||||||
| Net income (loss) | (6,805) | (6,805) | (6,141,476,000) | |||||||||||||
| Loss for the period | (6,141,476,000) | (6,141,476,000) | ||||||||||||||
| Remeasurement of defined benefit liabilities | 52,121,000 | 52,121,000 | ||||||||||||||
| Total comprehensive loss for the period | 52,121,000 | (6,141,476,000) | (6,089,355,000) | |||||||||||||
| Warrants exercised | 260,500,000 | 1,044,500,000 | 1,305,000,000 | |||||||||||||
| Bond with warrants issued | 609,366,000 | 609,366,000 | ||||||||||||||
| Disposal of treasury shares | 163,089,000 | (50,000,000) | 36,911,000 | 150,000,000 | ||||||||||||
| Ending balance, value at Dec. 31, 2025 | $ 50,000 | ₩ 50,000 | (36,558) | ₩ (36,558) | 13,442 | ₩ 13,442 | 26,407,738,000 | 46,566,573,000 | (50,000,000) | (690,292,000) | 125,654,000 | (75,558,054,000) | (3,198,381,000) | |||
| Ending balance, Shares at Dec. 31, 2025 | shares | 50,000 | 50,000 | ||||||||||||||
| IfrsStatementLineItems [Line Items] | ||||||||||||||||
| Net income (loss) | 456 | 456 | (2,997,895,000) | |||||||||||||
| Loss for the period | (2,997,895,000) | (2,997,895,000) | ||||||||||||||
| Remeasurement of defined benefit liabilities | 153,732,000 | 153,732,000 | ||||||||||||||
| Total comprehensive loss for the period | 153,732,000 | (2,997,895,000) | (2,844,163,000) | |||||||||||||
| Disposal of treasury shares | ₩ 128,000,000 | 113,236,000 | 14,765,000 | 128,001,000 | ||||||||||||
| Ending balance, value at Jun. 30, 2026 | $ 50,000 | $ (36,102) | $ 13,898 | ₩ 26,407,738,000 | ₩ 46,679,809,000 | ₩ (50,000,000) | ₩ (675,527,000) | ₩ 279,386,000 | ₩ (78,555,949,000) | ₩ (5,914,543,000) |